|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 帕博利珠单抗单用或与放疗联用治疗转移性非小细胞肺癌:两个随机试验的汇总分析显示文摘背景放疗可以提高整个机体对免疫治疗的应答。在Ⅱ期PEMBRO-RT研究和Ⅰ/Ⅱ期MDACC研究中,患有转移性非小细胞肺癌(NSCLC)的患者被随机分配入组,接受免疫治疗(帕博利珠单抗)+放疗联合疗法,或免疫治疗单一疗法。当上述2个研究单独分析时,联合疗法组显示出潜在获益。由于每个研究的样本量较小,缓解率和结局并未显示出统计学意义,然而却有显著的临床获益。因此,本研究进行汇总分析,来判断放疗是否会改善转移性NSCLC患者的免疫治疗应答。方法PEMBRO-RT和MDACC研究纳入标准:患者年龄≥18岁,患有转移性NSCLC,且有≥1处未经放疗照射的病灶,以便进行射野外应答监测。PEMBRO-RT研究纳入曾接受过化疗患者,MDACC研究纳入曾接受过治疗或新诊断患者。2个研究中的患者均未接受过免疫治疗。在PEMBRO-RT研究中患者被等比例随机分配入组,并根据吸烟状态进行分层(分为<10年组和≥10年组)。MDACC研究的患者根据放疗计划可行性被等比例随机分配入2个受试组。由于联合治疗组的干预本质,每个研究中的放疗均不适用盲法。在2个研究中,不论是否进行放疗,均静脉滴入帕博利珠单抗(每3周200 mg)。在PEMBRO-RT研究中,在放疗(24 Gy 3次分割照射)结束后1周给予第1剂帕博利珠单抗。在MDACC研究中,在第1次放疗(50 Gy 4次分割照射或45 Gy 15次分割照射)同时给予帕博利珠单抗。仅检测未经照射病灶的应答。本研究的终点为最佳射野外(远隔)应答率(ARR)、最佳射野外疾病控制率(ACR)、12周时ARR、12周时ACR、无进展生存期(PFS)和总生存期(OS)。2个研究的意向治疗(ITT)人群均纳入分析。PEMBRO-RT研究(NCT02492568)和MDACC研究(NCT02444741)均在ClinicalTrials.gov上注册。发现纳入148例患者,76例接受帕博利珠单抗治疗,72例接受帕博利珠单抗+放疗治疗。所有患者随访时间中位数为33个月[四分位距(IQR):32.4~33.6]。148例患者中124例(84%)组织学特征为非鳞癌,111例(75%)患者曾经接受过化疗。组间没有基线特征差异,包括PD-L1表达状态和转移灶体积。最常见的照射部位为肺转移灶(39%,28/72)、胸腔内淋巴结(21%,15/72)和非原发灶(17%,12/72)。帕博利珠单抗组和联合治疗组的最佳ARR分别为19.7%(15/76)和41.7%(30/72),OR=2.96,95%CI:1.42~6.20,P=0.0039;最佳ACR分别为43.4%(33/76)和65.3%(47/72),OR=2.51,95%CI:1.28~4.91,P=0.0071;PFS中位数分别为4.4(IQR:2.9~5.9)和9.0个月(IQR:6.8~11.2),HR=0.67,95%CI:0.45~0.99,P=0.045;OS中位数分别为8.7(IQR:6.4~11.0)和19.2个月(IQR:14.6~23.8),OR=0.67,95%CI:0.54~0.84,P=0.0004。在汇总分析中没有发现新的安全问题。解读帕博利珠单抗免疫疗法+放疗显著提高转移性NSCLC患者的应答和改善治疗结局。这些结果需要在三期临床试验中进行验证。 | 陈大卫(翻译) 于金明(校对) Willemijn S M E Theelen Vivek Verma Brian P Hobbs Heike M U Peulen Joachim G J V Aerts Idris Bahce Anna Larissa N Niemeijer Joe Y Chang Patricia M de Groot Quynh-Nhu Nguyen Nathan I Comeaux George R Simon Ferdinandos Skoulidis Steven H Lin Kewen He Roshal Patel John Heymach Paul Baas James W Welsh | 2021 | 中华肿瘤防治杂志2021，28，24： | 49 |
| 2 | Nat Genet:单细胞分析解开结直肠癌细胞的神秘面纱显示文摘结合单细胞基因组学和计算机技术,一个研究团队(包括来自杰克逊实验室(JAx)单细胞生物学主任Paul Robson博士在内)鉴定出了11种结直肠癌肿瘤的癌细胞组成及邻近的非癌细胞。这对于更好的肿瘤靶向诊断和治疗很重要。”使用单细胞测序。”JAX科学家、这篇发表在Nature Genetics上的文章共同第一作者Elise Courtois说道。”我们可以根据肿瘤中的细胞组成将结直肠癌进一步分类。因为每种亚型的肿瘤病人生存率存在差别,我们的方法将为肿瘤医生提供更多的关于肿瘤预后和治疗的信息。” | Huipeng Li, Elise T Courtois, Debarka Sengupta, Yuliana Tan Shyam Prabhakar Elise T Courtois, Yuliana Tan Paul Robson Debarka Sengupta Kok Hao Chen, Jolene Jie Lin Goh Paul Jongjoon Choi Say Li Kong, Axel M Hillmer Iain Beehuat Tan Clarinda Chua Iain Beehuat Tan Lim Kiat Hon Wah Siew Tan Mark Wong Lawrence J K Wee Iain Beehuat Tan Paul Robson Paul Robson Paul Robson | 2017 | 现代生物医学进展2017，17，15： | 37 |
| 3 | Cadherin-17:一种消化道腺癌诊断的有效标记显示文摘 | Su M C Yuan R H Lin C Y 饶秋(摘译) | 2008 | 临床与实验病理学杂志2008，24，5： | 26 |
| 4 | 血管周围脂肪组织中的Bmal1通过血管紧张素原转录调控管理静息期血压显示文摘血管周围脂肪组织(perivascular adipose tissue,PVAT)围绕血管,构成了在生理条件下保持血管张力所需的脉管系统的独特的功能整体层。然而,关于PVAT与血压调节之间的关系的资料很少,包括其对昼夜血压变化的潜在作用。 | Chang L Xiong W Zhao X Fan Y Guo Y Garcia-Barrio M Zhang J Jiang Z Lin JD Chen YE 刘青 叶鹏 | 2018 | 中华高血压杂志2018，26，2： | 23 |
| 5 | Phage therapy: An alternative to antibiotics in the age of multi-drug resistance显示文摘The practice of phage therapy, which uses bacterial viruses(phages) to treat bacterial infections, has been around for almost a century. The universal decline in the effectiveness of antibiotics has generated renewed interest in revisiting this practice. Conventionally, phage therapy relies on the use of naturally-occurring phages to infect and lyse bacteria at the site of infection. Biotechnological advances have further expanded the repertoire of potential phage therapeutics to include novel strategies using bioengineered phages and purified phage lytic proteins. Current research on the use of phages and their lytic proteins against multidrug-resistant bacterial infections, suggests phage therapy has the potential to be used as either an alternative or a supplement to antibiotic treatments. Antibacterial therapies, whether phage-or antibiotic-based, each have relative advantages and disadvantages; accordingly, many considerations must be taken into account when designing novel therapeutic approaches for preventing and treating bacterial infection. Although much about phages and human health is still being discovered, the time to take phage therapy serious again seems to be rapidly approaching. | Derek M Lin Britt Koskella Henry C Lin | 2017 | World Journal of Gastrointestinal Pharmacology and Therapeutics2017，8，3： | 20 |
| 6 | 功能的限制的积极选择而非松驰在鸡驯服期间驾驶视觉的进化显示文摘是由达尔文,注意了鸡有所有鸟,而是国内鸡和他们的野祖先之间的有趣的进化差别的最大的 phenotypic 差异,红 Junglefowl,是他们的比较地更弱的视觉。存在理论建议在国内鸡之中的减少的视觉英勇反映功能的限制的松驰在识别负责的内在的基因机制的视觉,而是证据上驾驶的变化因为这个变化决定性地没被描绘。这里,国内鸡的染色体宽的分析和红 Junglefowl 染色体为涉及视觉的发展的断然选择的基因显示出重要丰富。关于为在视网膜的这些基因的 mRNA 表示的水平国内鸡和他们的野祖先之间有重要差别。涉及视觉的发展的众多的另外的基因也在在国内鸡和他们的野祖先之间的 mRNA 表示显示出重要差别,特别地为与 phototransduction 和光敏电阻器开发联系的基因,例如 RHO (视紫红质) , GUCA1A, PDE6B 和 NR2E3。最后,我们在视觉描绘了 VIT 基因的潜在的角色,它在村庄鸡的视网膜经历了积极选择和 downregulated 表示。总的来说,我们的结果建议净化选择的那种积极选择,而非松驰,在国内鸡贡献了视觉的进化。怀有更弱的视觉的国内鸡的祖先可能显示出减少的害怕回答和警戒,使他们更安逸无意识地被选择或驯养。 | Ming-Shan Wang Rong-wei Zhang Ling-Yan Su Yah Li Min-Sheng Peng He-Qun Liu Lin Zeng David M Irwin Jiu-Lin Du Yong-Gang Yao Dong-Dong Wu Ya-Ping Zhang | 2016 | Cell Research2016，26，5： | 15 |
| 7 | C-type lectin receptor-induced NF-κB activation in innate immune and inflammatory responses显示文摘C 类型 lectin 受体(CLR ) 属于在他们的细胞外的域上包含糖类识别域(CRD ) 和钙绑定地点的蛋白质的一个大家庭。最近的研究显示许多 CLR 例如 Dectin-1, Dectin-2 和 Mincle,作为从感染的微生物认出糖类 ligands 的模式识别受体(PRR ) 工作。在 ligand 绑定之上,这些 CLR 通过他们的自己的 immunoreceptor 导致多重信号 transduction 串联基于酷氨酸的激活主题(ITAM ) 或与象 FcRγ 那样的包含 ITAM 适配器蛋白质交往;。新兴的证据显示导致 CLR 的发信号串联导致原子因素 kappaB 的激活(NF-κ B ) 通过一条 Syk 依赖、 CARD9 依赖的小径的 transcriptional 因素的家庭。NF-κ 的激活; B 在跟随微生物引起的感染和织物损坏的天生的有免疫力、煽动性的回答的正式就职起一个关键作用。在这评论,我们将在 CLR 导致的信号 transduction 小径上总结最近的进步,并且这些 CLR 怎么激活 NF-κ B 并且贡献天生的有免疫力、煽动性的回答。 | Lara M Kingeter Xin Lin | 2012 | Cellular & Molecular Immunology2012，9，2： | 14 |
| 8 | China Patient-centered Evaluative Assessment of Cardiac Events Prospective Study of Acute Myocardial Infarction: Study Design显示文摘 | Rachel P Dreyer Xi Li Xue Du Nicholas S Downing Li Li Hai-Bo Zhang Fang Feng Wen-Chi Guan Xiao Xu Shu-Xia Li Zhen-Qiu Lin Frederick A Masoudi John A Spertus Harlan M Krumholz Li-Xin Jiang | 2016 | Chinese Medical Journal2016，，1： | 13 |
| 9 | Nat Chem Biol:利用CRISPR-Cas9激活细菌中沉默的基因簇,有望发现新的药物显示文摘为了抵抗疾病,很多医药库中的武器是从细菌当中获得的。如今,利用CRISPR-Cas9基因编辑技术。研究人员揭示出沉默基因中隐藏着的更多潜在的宝藏。作为一类常见的细菌。链霉菌被用来产生很多作为抗生素、抗癌试剂和其他药物的化合物。在一项新的研究中。来自美国伊利诺伊大学和新加坡科技研究局的研究人员利用CRISPR-Cas9技术激活链霉菌中不表达的或者说沉默的基因簇。 | Mingzi M Zhang, Wan Lin Yeo, Ee Lui Ang, Huimin Zhao Fong Tian Wong, Elena Heng Yajie Wang, Shangwen Luo, Ryan E Cobb, Behnam Enghiad, Huimin Zhao Yee Hwee Lim | 2017 | 现代生物医学进展2017，17，17： | 12 |
| 10 | Advances in immuno-oncology biomarkers for gastroesophageal cancer:programmed death ligand 1,microsatellite instability,and beyond显示文摘Blockade of the programmed death ligand 1(PD-L1) and programmed cell death 1(PD-1) receptor axis represents an effective form of cancer immunotherapy. Preclinical evidence initially suggested that gastric and gastroesophageal junction(GEJ) cancers are potentially immunotherapy-sensitive tumors. Early phase clinical trials have demonstrated promising antitumor activity with PD-1/PD-L1 blockade in advanced or metastatic gastric/GEJ cancer. Microsatellite instability(MSI) and PD-L1 expression have been shown to predict higher response to PD-1 inhibitors as highlighted by the recent approvals of pembrolizumab in treatmentrefractory solid tumors with MSI status and the thirdline or greater treatment of PD-L1 positive advanced gastric/GEJ cancers. However, predictive and prognostic biomarkers remain an ongoing need. In this review, we detail the preclinical evidence and early tissue biomarker analyses illustrating potential predictive biomarkers to PD-1/PD-L1 blockade in gastric/GEJ cancer. We also review the clinical development of PD-1/PD-L1 inhibitors in gastric/GEJ cancer and highlight several areas in need of future investigation in order to optimize the efficacy of PD-1/PD-L1 blockade in gastric/GEJ cancer. | Emily M Lin Jun Gong Samuel J Klempner Joseph Chao | 2018 | World Journal of Gastroenterology2018，24，25： | 10 |
| 11 | 桑叶多糖对早期断奶仔猪生长性能、腹泻、血液指标和肠道菌群的影响显示文摘研究旨在探讨日粮补充桑叶多糖(MLPs)对早期断奶仔猪生长性能、腹泻、血液生化指标和肠道菌群的影响。共选取(28±2)日龄、体重为(9.18±0.46)kg的'杜洛克×长白×约克夏'杂交断奶仔猪150头,随机分成5个处理组,每组6个重复,每个重复5头猪。饮食处理如下:对照组(CT):基础日粮(BD);低剂量桑叶多糖组(LT):0.3 g·kg-1MLPs+BD;中剂量桑叶多糖组(MT):0.6 g·kg-1MLPs+BD;高剂量桑叶多糖组(HT):0.9 g·kg-1MLPs+BD;抗生素处理组(AT):0.15 g·kg-1金霉素+BD。分别在第0、10、21天的早晨,每头猪空腹测量体重并记录采食量,这些数据用来计算平均日增重(ADG)、平均日采食量(ADFI)和料重比(F/G)。每天两次(上午和下午)对每头仔猪的腹泻状况进行检查并记录。在试验结束时,收集血液样本用于生化分析,并收集盲肠、结肠和直肠内容物进行识别和量化相关的肠道菌群。研究结果表明,MLPs处理组间的日增重、平均日采食量和料重比无显著差异(P>0.05),但低剂量组(LT)、中剂量组(MT)、高剂量组(HT)的平均日采食量高于对照组(CT)和抗生素组(AT)。并且,LT、MT和HT组的料重比低于CT和AT组。与CT和AT组相比,LT、MT和HT组仔猪的腹泻发病率也显著降低(P<0.05)。生化分析表明,MLPs各处理组仔猪的血糖(GLU)水平均显著低于CT或AT组(P<0.05)。MT和HT组血液尿素氮(BUN)水平与CT和AT组存在显著差异(P<0.05),HT组T3水平显著高于CT和AT组(P<0.05)。虽然MLPs各处理组的T4水平与AT组并没有显著差异(P>0.05),但MT组的胰岛素样生长因子Ⅰ(IGF-Ⅰ)和生长激素(GH)水平较CT或AT组均显著升高(P<0.05)。LT、MT和HT 3组在抑制肠道大肠杆菌生长和促进肠道乳酸杆菌和双歧杆菌生长的整体效果上均优于CT和AT组。值得注意的是,与CT和AT组相比,HT组(0.9 g·kg-1MLPs)对抑制肠道大肠杆菌以及促进肠道有益菌群具有更显著效果(P<0.05)。结果表明,日粮添加桑叶多糖可以改善早期断奶仔猪肠道菌群的生态环境,降低腹泻率,提高整体生长性能。 | Zhao X J Lin L Luo Q L Ye M Q Luo G Q Kuang Z S | 2015 | 饲料博览2015，0，7： | 7 |
| 12 | Convergent genomic signatures of high-altitude adaptation among domestic mammals显示文摘Abundant and diverse domestic mammals living on the Tibetan Plateau provide useful materials for investigating adaptive evolution and genetic convergence.Here,we used 327 genomes from horses,sheep,goats,cattle,pigs and dogs living at both high and low altitudes,including 73 genomes generated for this study,to disentangle the genetic mechanisms underlying local adaptation of domestic mammals.Although molecular convergence is comparatively rare at the DNA sequence level,we found convergent signature of positive selection at the gene level,particularly the EPAS1 gene in these Tibetan domestic mammals.We also reported a potential function in response to hypoxia for the gene C10 orf67,which underwent positive selection in three of the domestic mammals.Our data provide an insight into adaptive evolution of high-altitude domestic mammals,and should facilitate the search for additional novel genes involved in the hypoxia response pathway. | Dong-Dong Wu Cui-Ping Yang Ming-Shan Wang Kun-Zhe Dong Da-Wei Yan Zi-Qian Hao Song-Qing Fan Shu-Zhou Chu Qiu-Shuo Shen Li-Ping Jiang Yan Li Lin Zeng He-Qun Liu Hai-Bing Xie Yun-Fei Ma Xiao-Yan Kong Shu-Li Yang Xin-Xing Dong Ali Esmailizadeh David M Irwin Xiao Xiao Ming Li Yang Dong Wen Wang Peng Shi Hai-Peng Li Yue-Hui Ma Xiao Gou Yong-Bin Chen Ya-Ping Zhang | 2020 | National Science Review2020，7，6： | 7 |
| 13 | 术前放疗不足以控制局部进展期直肠癌患者的侧方复发:一项随机对照研究的事后分析显示文摘背景:新辅助放化疗(neoadjuvant chemoradiotherapy,nCRT)后全直肠系膜切除(total mesorectal excision,TME)降低了直肠癌的局部复发率。然而在低位局部进展期直肠癌(locally advanced rectal cancer,LARC)患者中,侧方复发问题仍有待解决。目的:本研究旨在确定新辅助放疗在解决侧方复发方面的问题,以及哪些亚组患者可能最适合接受侧方淋巴结清扫术(lateral lymph node dissection,LLND)。 | 李来元 杨熊飞 XIE Y M LIN J X WANG X L | 2021 | 结直肠肛门外科2021，27，5： | 6 |
| 14 | 帕博利珠单抗联合以铂类为基础的化疗治疗非小细胞肺癌合并稳定性脑转移患者的结局:KEYNOTE-021、-189和-407研究的汇总分析显示文摘背景与目的此项探索性分析回顾评价了晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的结局,旨在确定基线时合并脑转移是否会影响一线应用帕博利珠单抗联合化疗(pembrolizumab plus chemotherapy,PC)比对单用化疗的疗效。患者和方法对KEYNOTE-021队列G(非鳞癌)、KEYNOTE-189(非鳞癌)和KEYNOTE-407(鳞癌)三项研究晚期NSCLC患者的数据进行汇总分析。患者接受含铂两药化疗和/或35个周期帕博利珠单抗治疗(每3周200 mg)。所有研究均纳入了经治或初治的稳定性脑转移患者(KEYNOTE-189与KEYNOTE-407研究纳入初治脑转移患者)。经治的脑转移患者已处于病情稳定的状态≥2周(KEYNOTE-021队列G患者≥4周),无新发或脑转移病灶扩大的证据且入组前至少3天以上未使用激素。初治的无症状脑转移患者需定期接受脑部影像学检查。结果共纳入1298例患者,其中171例有基线脑转移,1127例无脑转移。两组的中位随访时间(范围)在数据截止时分别为10.9(0.1-35.1)个月和11.0(0.1-34.9)个月。合并脑转移和无脑转移患者的总生存期[0.48(95%CI:0.32-0.70)和0.63(95%CI:0.53-0.75)]和无进展生存期[0.44(95%CI:0.31-0.62)和0.55(95%CI:0.48-0.63)]的风险比(PC/化疗)相似。合并脑转移的患者中,PC组和单用化疗组患者的中位总生存期分别为18.8个月和7.6个月,中位无进展生存期分别为6.9个月和4.1个月。无论是否合并脑转移,PC组患者的客观缓解率都高于单用化疗组,且缓解持续时间有显著延长。合并脑转移的患者中,PC组与单用化疗组的治疗相关不良事件发生率分别为88.2%和82.8%;而无脑转移的患者中,两组治疗相关不良事件的发生率分别为94.5%和90.6%。结论无论是否合并脑转移,与单用化疗相比,帕博利珠单抗联合以铂类为基础的组织学特异性化疗可改善所有PD-L1亚组的临床结局,其中包括PD-L1肿瘤比例评分<1%的患者,并且在晚期NSCLC患者中安全性良好。该方案是晚期NSCLC初治患者的标准方案,并可用于合并稳定性脑转移的患者。 | 周清(翻译校对) Steven F Powell Delvys Rodríguez-Abreu Corey J Langer Ali Tafreshi Luis Paz-Ares Hans-Georg Kopp Jeronimo Rodríguez-Cid Dariusz M Kowalski Ying Cheng Takayasu Kurata Mark M Awad Jinaxin Lin Bin Zhao M Catherine Pietanza Bilal Piperdi Marina C Garassino | 2022 | 中国肺癌杂志2022，25，1： | 6 |
| 15 | National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants显示文摘 | Goodarz Danaei Mariel M Finucane Yuan Lu Gitanjali M Singh Melanie J Cowan Christopher J Paciorek John K Lin Farshad Farzadfar Young-Ho Khang Gretchen A Stevens Mayuree Rao Mohammed K Ali Leanne M Riley Carolyn A Robinson Majid Ezzati | 2011 | The Lancet2011，，9785： | 6 |
| 16 | Age and menopausal status are important factors influencing the serum human epididymis secretory protein 4 level:a prospective cross-sectional study in healthy Chinese people显示文摘Background::Human epididymis secretory protein 4(HE4)is a new ovarian cancer biomarker.The factors influencing HE4 levels are not clear,and the reference data in China are limited.Here,we aim to evaluate the effects of menopause and age on HE4 levels and to provide a possible reference value for HE4 in healthy Chinese people.Methods::A total of 2493 healthy females aged 40 years or older were recruited from March 2013 to March 2017 with the cooperation of four medical institutions across Beijing,China.The serum levels of HE4 and cancer antigen 125(CA125)were measured by enzyme-linked immunosorbent assay.The Wilcoxon rank-sum test of variance and a stratified analysis were used to analyze the relationships among age,menopausal status,and levels of HE4 or CA125.Confidence intervals(5%-95%)were determined for reference ranges in different populations.Results::There was a statistically significant difference in median HE4 levels between the post-menopausal(n=2168)and premenopausal groups(n=325)(36.46 vs.24.04 pmol/L,Z=-14.41,P<0.001).HE4 increased significantly with age in the post-menopausal groups(H=408.18,P<0.001)but not in the pre-menopausal subjects(Z=-0.43,P=0.67).The upper 95th percentile of HE4 levels were 44.63 pmol/L for pre-menopausal women,78.17 pmol/L for post-menopausal women,and 73.3 pmol/L for all women.In the post-menopausal population,the HE4 reference ranges were 13.15 to 47.31,14.31 to 58.04,17.06 to 73.51,24.50 to 115.25,and 35.71 to 212.37 pmol/L for different age groups from forty divided by decade.The CA125 level was affected mainly by menopausal status and not age.Conclusions::Menopausal status and age were both important factors influencing the level of HE4,and age affected HE4 levels mainly in post-menopausal women.The HE4 level was higher in the post-menopausal population than in the pre-menopausal population and increased with age. | Hong-Yan Cheng Lin Zeng Xue Ye Rui-Qiong M a Zhi-Jian Tang Hong-Ling Chu Yi-M ing Zhao Li-Rong Zhu Yu-Nong Gao Xiao-Hong Chang Heng Cui | 2020 | Chinese Medical Journal2020，，11： | 6 |
| 17 | Up-regulation of Bcl-2 is required for the progression of prostate cancer cells from an androgen-dependent to an androgen-independent growth stage显示文摘Bcl-2 是 anti-apoptotic oncoprotein,它的蛋白质层次相反地在许多癌症与预后被相关。然而,在前列腺癌症的前进的 Bcl-2 的角色不是清楚的。这里,我们报导 Bcl-2 从一个雄激素依赖者为 LNCaP 前列腺癌症细胞的前进被要求到一个雄激素无关的生长阶段。Bcl-2 的信使 rna 和蛋白质层次显著地在雄激素无关的前列腺癌症被增加在雄激素无关的前列腺癌症房间的 Bcl-2 的调停 cells.shRNA 的基因 silencing 导致 promotesUV 的 apoptosis 并且压制前列腺肿瘤的生长体内。在在形成的雄激素剥夺条件结果下面的 Growingandrogen 依赖的房间 ofandrogen 独立的殖民地;并且到 androgen-independentgrowth 的从雄激素依赖者的转变被 Bcl-2 对手 Bax 或 Bcl-2 shRNA 的宫外的表示堵住。因此,我们的结果证明 Bcl-2 为 androgen-independentprostate 癌症细胞的幸存是批评的不仅,但是也为前列腺癌症细胞的前进被要求从对一个雄激素无关的生长阶段 anandrogen 依赖。 | Yuting Lin Junichi Fukuchi Richard A Hiipakka John M Kokontis Jialing Xiang | 2007 | Cell Research2007，17，6： | 5 |
| 18 | 新辅助放化疗联合全直肠系膜切除术后接受辅助化疗不能改善Ⅱ/Ⅲ期直肠癌患者的无复发生存率显示文摘目的:目前,NCCN指南建议对局部进展期Ⅱ/Ⅲ期直肠癌先行新辅助放化疗(nCRT),然后行全直肠系膜切除术(TME)和辅助化疗。辅助化疗的肿瘤学获益尚未得到进一步证实。本研究的目的是评估nCRT+TME手术后接受辅助化疗的直肠癌患者肿瘤复发和生存情况。方法:本研究是在南加州的14家医院和相关诊所完成的回顾性研究,研究对象为2005年1月1日至2016年12月31日接受手术治疗的862例Ⅱ/Ⅲ期直肠癌患者,无论是否行辅助化疗,纳入研究的患者均接受了新辅助化疗以及全直肠系膜切除术。主要终点是无复发生存率。 | 李来元 VOSS R K LIN J C ROPER M T | 2020 | 结直肠肛门外科2020，26，2： | 5 |
| 19 | Interventional radiology in living donor liver transplant显示文摘The shortage of deceased donor liver grafts led to the use of living donor liver transplant(LDLT).Patients who un-dergo LDLT have a higher risk of complications than those who undergo deceased donor liver transplantation(LT).Interventional radiology has acquired a key role in every LT program by treating the majority of vascular and nonvascular post-transplant complications,improving graft and patient survival and avoiding,in the majority of cases,surgical revision and/or re-transplant.The aim of this paper is to review indications,diagnostic modalities,technical considerations,achievements and potential complications of interventional radiology procedures after LDLT. | Yu-Fan Cheng Hsin-You Ou Chun-Yen Yu Leo Leung-Chit Tsang Tung-Liang Huang Tai-Yi Chen Hsien-Wen Hsu Allan M Concerjero Chih-Chi Wang Shih-Ho Wang Tsan-Shiun Lin Yueh-Wei Liu Chee-Chien Yong Yu-Hung Lin Chih-Che Lin King-Wah Chiu Bruno Jawan Hock-Liew Eng Chao-Long Chen | 2014 | World Journal of Gastroenterology2014，20，20： | 5 |
| 20 | Clinicopathological parameters predicting recurrence of pT1N0 esophageal squamous cell carcinoma显示文摘AIM To identify the clinicopathological characteristics of pT1 N0 esophageal squamous cell carcinoma(ESCC) that are associated with tumor recurrence. METHODS We reviewed 216 pT1 N0 thoracic ESCC cases who underwent esophagectomy and thoracoabdominal two-field lymphadenectomy without preoperative chemoradiotherapy. After excluding those cases with clinical follow-up recorded fewer than 3 mo and those who died within 3 mo of surgery, we included 199 cases in the current analysis. Overall survival and recurrencefree survival were assessed by the Kaplan-Meier method, and clinicopathological characteristics associated with any recurrence or distant recurrence were evaluated using univariate and multivariate Cox proportional hazards models. Early recurrence(≤ 24 mo) and correlated parameters were assessed using univariate and multivariate logistic regression models.RESULTS Forty-seven(24%) patients had a recurrence at 3 to 178(median, 33) mo. The 5-year recurrence-free survival rate was 80.7%. None of 13 asymptomatic cases had a recurrence. Preoperative clinical symptoms, upper thoracic location, ulcerative or intraluminal mass macroscopic tumor type, tumor invasion depth level, basaloid histology, angiolymphatic invasion, tumor thickness, submucosal invasion thickness, diameter of the largest single tongue of invasion, and complete negative aberrant p53 expression were significantly related to tumor recurrence and/or recurrence-free survival. Upper thoracic tumor location, angiolymphatic invasion, and submucosal invasion thickness were independent predictors of tumor recurrence(Hazard ratios = 3.26, 3.42, and 2.06, P < 0.001, P < 0.001, and P = 0.002, respectively), and a nomogram for predicting recurrence-free survival with these three predictors was constructed. Upper thoracic tumor location and angiolymphatic invasion were independent predictors of distant recurrence. Upper thoracic tumor location, angiolymphatic invasion, submucosal invasion thickness, and diameter of the largest single tongue of invasion were independent predictors of early recurrence.CONCLUSION These results should be useful for designing optimal individual follow-up and therapy for patients with T1 N0 ESCC. | Li-Yan Xue Xiu-Min Qin Yong Liu Jun Liang Hua Lin Xue-Min Xue Shuang-Mei Zou Mo-Yan Zhang Bai-Hua Zhang Zhou-Guang Hui Zi-Tong Zhao Li-Qun Ren Yue-Ming Zhang Xiu-Yun Liu Yan-Ling Yuan Jian-Ming Ying Shu-Geng Gao Yong-Mei Song Gui-Qi Wang Sanford M Dawsey Ning Lu | 2018 | World Journal of Gastroenterology2018，24，45： | 4 |
您所在的机构暂未开通此部分的功能，请联系管理员